, /PRNewswire/ -- "According to the latest BCC Research study, the demand for " " is estimated to increase from in 2023 to reach by 2029, at a compound annual growth rate (CAGR) of 7.5% from 2024 through 2029." The report on the global market for recombinant proteins provides a comprehensive analysis of current trends and prospects in this industry.
It examines key drivers, such as increasing demand for biopharmaceuticals and advancements in genetic engineering, alongside challenges and opportunities impacting market growth. Segmentation by product type includes hormones, cytokines, enzymes, antigens, antibodies, and others, with host cell types categorized as mammalian, insect, yeast fungi, bacterial, and others. Applications covered are therapeutics and vaccines, biomedical research, and diagnostics.
Geographically, the market is analyzed across , , , and the Rest of the World, with detailed country-level insights provided. The competitive landscape features profiles of key players, offering insights into their strategies, financials, product portfolios, and recent developments. This comprehensive overview excludes proteins produced through hybridoma techniques and does not cover recombinant COVID-19 vaccines.
Biopharmaceuticals are increasingly important for treating diseases like cancer and autoimmune disorders, driven by an aging population, and rising chronic illnesses. Companies are investing heavily in research to develop new therapeutic proteins to improve treatment .
